Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalen
![]() |
Scooped by
Association Revenue Partners
onto Industry 411 - Waste Management September 10, 11:31 AM
|
No comment yet.